Companies

Sep, 2023. the class 1 new drug Narlumosbart for Injection(JMT103) developed by Shanghai JMT-Bio Technology Co. Ltd is approved by China NMPA . This drug is indicated for the treatment for adult patients with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. Narlumosbart Injection is a recombinant human anti-receptor activator of NF-κB ligand (RANKL) monoclonal antibody. It can inhibit the activity of RANKL through specifically binding to RANKL on the cell membrane, thereby inhibiting its involvement in mediating osteolysis…

Aug, 2023. China NMPA approved the Category 1 innovative drug Sunvozertinib Tablets (Chinese trade name:SHUWUZHE) of Dizal (Jiangsu) Pharmaceutical Co., Ltd for use in adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy. Non-small cell lung cancer (NSCLC) is the most common type of cancer in China, with the highest incidence and mortality rates. EGFR is the most common driver gene mutation in NSCLC, and the EGFR Exon20ins mutation is the most…

Jun,2023. Retagliptin Phosphate Tablets, the Class 1. New drug from Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of type 2 diabetes, is approved by China NMPA.

July 2023, Skyline Therapeutics announced that the U.S. FDA has cleared its IND application for Phase I/IIa clinical trial of SKG0106, a one-time intravitreally delivered AAV gene therapy for the treatment of neovascular age-related macular degeneration (nAMD). Global Phase I clinical trial will be initiated soon. Age-related macular degeneration (AMD) is a progressive disease that can severely impair central vision and is a leading cause of irreversible blindness in the elderly. Neovascular age-related macular degeneration (nAMD), characterized by the formation of choroidal neovascularization (CNV), bleeding, and exudation, accounts for up…

June, 2023,Eccogene (Shanghai) Co. Ltd. (Eccogene) announced that it has received 180 million yuan (approximately $25 million USD) in Series B financing.

When will KarXT be available on the market? Karuna’s drug for schizophrenia,KarXT attracted public attention so much. Investors and patients have great concern on KarXT release date and KarXT FDA approval timeline. According to the most recent news, Karuna plans to submit a New Drug Application (NDA) for KarXT within this year.

Ivonescimab (PD-1/VEGF BsAbs,AK112),  developed independently by Akeso, Inc, is the world’s first PD-1/VEGF bispecific antibody for clinical trail. Ivonescimab injection(AK112) has received 3 breakthrough therapy designation(BTD) for NSCLC.

June, 2023, Guangzhou JOYO Pharma Co., Ltd (JOYO PHARMA)announced that it has completed the pre-C round of financing of more than 100 million yuan.

Cholesgen completed A-round financing of more than 100 million RMB, deeply cultivated the field of cholesterol metabolism. Here is introduction of Cholesgen (Shanghai) Co. Ltd.

On June 5th, Beijing VDJBio Co., Ltd.(VDJBio) announced the completion of its Series C financing round.VDJ-001 is a recombinant humanized monoclonal antibody injection that targets interleukin-6 (IL-6) receptors.